Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

Johnson & Johnson today announced 12-month pilot-phase data from the OMNY-AF study, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation (AFib), during the 31st Annual AF Symposium in Boston. Initial results for 12-month outcomes across the 30-patient pilot cohort show investigators achieved 100% acute procedural success with no procedure-associated adverse events, while 56.7% of cases were performed with zero fluoroscopy and 90% of patients achieved primary effectiveness at 12 months.ⁱ

OMNY-AF is a prospective, single-arm, multi-center clinical trial conducted across more than 40 sites in the U.S. and Australia.^vi The study pairs the OMNYPULSE Catheter, a 12 mm large-tip focal catheter featuring contact-force sensing and bipolar, biphasic pulse delivery with the TRUPULSE Generator. This integrated design combines precise mapping, controlled energy delivery and live feedback through the PF index on the CARTO 3 System.^vii The OMNYPULSE Platform is not currently approved in any region of the world.

“The 12-month data provide encouraging early evidence on the OMNY-AF study with promising safety outcomes – no procedure-related adverse events or MRI-detected cerebral lesions – across eight centers in the pilot phase ⁱ. In my cases during the ongoing OMNY-AF trial, the seamless integration of advanced mapping, ultrasound, and PF Index with contact force were valuable for precise and efficient pulsed field energy delivery,” said Dinesh Sharma, M.D.¹, Section Head of Cardiac Electrophysiology at the Naples Heart Institute, the study presenting author.

Alongside the OMNY-AF data, Johnson & Johnson is highlighting new findings related to the VARIPULSE Platform. Data presented by Andrea Natale, M.D.², and simultaneously published in JACC Clin Electrophysiology, by Moussa Mansour, M.D.³ examined the incidence of neurovascular events following the workflow enhancements and the introduction of an optimized irrigation flow rate. Notably, the platform sustained a low neurovascular event rate of 0.22% in 6,811 patients after implementation of both workflow enhancements and the updated irrigation rate.ⁱⁱ

Additional VARIPULSE Platform data presented at AF Symposium adds to the growing body of evidence underscoring the platform’s consistent and favorable safety profile across a range of clinical and real-world settings, including:

• VARISURE Safety survey data presented by Christopher Porterfield, M.D.⁴: Early results from this physician survey on 850 procedures indicated low complication rates with a 1.9% rate of primary adverse events, a 0.2% incidence of neurovascular events and no reported cases of coronary spasm or death. Same-day discharge was achieved in 87.9% of patients.ⁱⁱⁱ
• REAL AF registry analysis presented by Mohammad-Ali Jazayeri, M.D.⁵: Results from the REAL AF registry showed excellent acute safety outcomes of the VARIPULSE Catheter, with a low overall acute safety event rate of 0.5% with no neurovascular events, high rates of same-day discharge and no observed differences in safety outcomes across AFib classifications.^iv
• Irrigation Flow Optimization research presented by Fengwei Zou, M.D.⁶: Preclinical data demonstrated parity between the 4 mL/min and 30 mL/min irrigation rates in microbubble generation, hemolysis and lesion depth when using the VARIPULSE Catheter, while confirming that higher irrigation significantly reduced electrode surface heating.^v

“These data reinforce confidence in the consistency of safety outcomes observed across Johnson & Johnson’s electrophysiology portfolio. As a relatively new energy modality, pulse field ablation technologies should be individually evaluated for safety and reproducibility in atrial fibrillation ablation,” said Gregory Michaud, M.D., Chief Medical and Scientific Officer, Electrophysiology, MedTech, Johnson & Johnson. “As pulsed field ablation continues to evolve, rigorous evidence generation and transparent data sharing will be essential to advancing the science and enabling the next wave of innovation with this technology.”